CIM LLC’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.8M Buy
374,817
+158,732
+73% +$7.52M 1.99% 20
2025
Q4
$11M Sell
216,085
-1,206
-0.6% -$61.7K 1.44% 23
2025
Q3
$12.1M Sell
217,291
-8,307
-4% -$486K 1.58% 23
2025
Q2
$15.6M Buy
225,598
+5,377
+2% +$366K 2.1% 20
2025
Q1
$15.3M Buy
220,221
+8,398
+4% +$694K 2.27% 19
2024
Q4
$18.2M Sell
211,823
-8,593
-4% -$929K 2.6% 17
2024
Q3
$26.2M Buy
220,416
+43
+0% +$5.74K 3.78% 4
2024
Q2
$28.8M Sell
220,373
-1,912
-0.9% -$253K 4.34% 2
2024
Q1
$28.5M Sell
222,285
-5,337
-2% -$635K 4.32% 2
2023
Q4
$28.3M Buy
227,622
+3,454
+2% +$342K 4.41% 2
2023
Q3
$20.4M Buy
224,168
+14,108
+7% +$1.24M 3.88% 2
2023
Q2
$17M Sell
210,060
-5,138
-2% -$420K 3.18% 8
2023
Q1
$17.1M Sell
215,198
-14,400
-6% -$1.02M 3.39% 5
2022
Q4
$16M Sell
229,598
-84,188
-27% -$4.94M 3.18% 7
2022
Q3
$16.7M Sell
313,786
-16,144
-5% -$865K 3.52% 6
2022
Q2
$18M Sell
329,930
-14,162
-4% -$786K 3.73% 3
2022
Q1
$20.8M Sell
344,092
-63,732
-16% -$3.27M 3.87% 2
2021
Q4
$19.4M Sell
407,824
-20,126
-5% -$1.09M 3.62% 6
2021
Q3
$24.3M Sell
427,950
-11,314
-3% -$547K 3.77% 7
2021
Q2
$21.8M Buy
439,264
+1,812
+0.4% +$70.2K 3.55% 7
2021
Q1
$16.7M Sell
437,452
-7,734
-2% -$275K 2.99% 14
2020
Q4
$15.9M Buy
445,186
+988
+0.2% +$34.1K 2.93% 14
2020
Q3
$15.9M Buy
444,198
+7,514
+2% +$250K 3.24% 11
2020
Q2
$14.3M Sell
436,684
-1,776
-0.4% -$56.7K 4.19% 6
2020
Q1
$13.2M Sell
438,460
-7,290
-2% -$217K 5.01% 2
2019
Q4
$12.9M Buy
445,750
+46,620
+12% +$1.29M 4.04% 6
2019
Q3
$10.3M Buy
399,130
+6,952
+2% +$176K 3.56% 11
2019
Q2
$10M Buy
392,178
+7,722
+2% +$191K 3.45% 15
2019
Q1
$10.1M Buy
384,456
+4,722
+1% +$116K 3.7% 10
2018
Q4
$8.75M Buy
379,734
+4,602
+1% +$102K 3.83% 10
2018
Q3
$8.84M Sell
375,132
-30,362
-7% -$741K 3.23% 17
2018
Q2
$9.35M Buy
405,494
+4,404
+1% +$105K 3.37% 17
2018
Q1
$9.88M Sell
401,090
-3,016
-0.7% -$79.2K 3.83% 10
2017
Q4
$10.8M Buy
404,106
+16,040
+4% +$408K 4.25% 6
2017
Q3
$9.34M Sell
388,066
-1,078
-0.3% -$24.4K 3.87% 9
2017
Q2
$8.35M Sell
389,144
-3,098
-0.8% -$62.5K 3.57% 15
2017
Q1
$6.72M Buy
392,242
+2,090
+0.5% +$36.4K 3.03% 19
2016
Q4
$7M Buy
390,152
+69,948
+22% +$1.27M 3.51% 17
2016
Q3
$6.66M Buy
320,204
+5,042
+2% +$125K 3.12% 19
2016
Q2
$8.47M Buy
315,162
+1,620
+0.5% +$44.4K 4.24% 12
2016
Q1
$8.5M Sell
313,542
-4,098
-1% -$110K 4.2% 12
2015
Q4
$9.22M Buy
317,640
+2,414
+0.8% +$66.8K 4.48% 9
2015
Q3
$8.55M Buy
315,226
+938
+0.3% +$26.6K 4.32% 13
2015
Q2
$8.61M Sell
314,288
-98,376
-24% -$2.77M 4.08% 14
2015
Q1
$11M Buy
412,664
+4,698
+1% +$108K 5.15% 1
2014
Q4
$8.63M Sell
407,966
-10,306
-2% -$230K 4.08% 13
2014
Q3
$9.96M Buy
418,272
+1,170
+0.3% +$26.9K 4.94% 5
2014
Q2
$9.63M Sell
417,102
-4,856
-1% -$107K 4.85% 3
2014
Q1
$9.63M Sell
421,958
-17,462
-4% -$372K 5.13% 1
2013
Q4
$8.12M Buy
439,420
+5,020
+1% +$87.5K 4.42% 9
2013
Q3
$7.35M Buy
434,400
+220
+0.1% +$3.7K 4.56% 4
2013
Q2
$6.73M Buy
+434,180
New +$7.23M 4.4% 8

Other funds holding NVO

CIM LLC's NVO Position: Q1 2026 in Review

CIM LLC increased its Novo Nordisk (NVO) stake by 73% in Q1 2026, buying an estimated $7.52M and bringing the position to 374,817 shares worth $13.8M. The position accounts for 1.99% of the portfolio, ranked #20.

CIM LLC first reported a position in NVO in Q2 2013 and has held it in 52 quarters since. The position peaked at $28.8M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • CIM LLC held 374,817 shares of Novo Nordisk worth $13.8M as of Q1 2026.
  • CIM LLC bought 158,732 Novo Nordisk shares in Q1 2026, an estimated $7.52M.
  • Novo Nordisk made up 1.99% of CIM LLC's portfolio in Q1 2026, its #20 holding.
  • CIM LLC first reported a position in Novo Nordisk in Q2 2013 and has held it in 52 quarters since.
  • CIM LLC's Novo Nordisk position peaked at $28.8M in Q2 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on CIM LLC's 13F filing for Q1 2026, filed 18 May 2026.